We are live on
!
Find out more
HS
HighVista Strategies Portfolio holdings
AUM
$362M
1-Year Est. Return
230.96%
This Fund
S&P 500
This Quarter
Est. Return
+3.78%
1 Year Est. Return
+230.96%
3 Year Est. Return
+518.4%
5 Year Est. Return
+644.94%
10 Year Est. Return
+2,223.31%
AUM
$274M
AUM Growth
-$6.67M
(-2.4%)
Cap. Flow
-$848K
Cap. Flow
% of AUM
-0.31%
Top 10 Holdings %
Top 10 Hldgs %
29.37%
Holding
164
New
33
Increased
27
Reduced
41
Closed
27
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
CTLT
CATALENT, INC.
CTLT
|
+$4.22M |
| 2 |
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
|
+$4.16M |
| 3 |
HCP
HashiCorp, Inc. Class A Common Stock
HCP
|
+$4.05M |
| 4 |
Salesforce
CRM
|
+$2.28M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$2.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
SP
SP Plus Corporation
SP
|
+$4.12M |
| 2 |
Orthofix Medical
OFIX
|
+$2.44M |
| 3 |
IDEAYA Biosciences
IDYA
|
+$2.31M |
| 4 |
Immunocore
IMCR
|
+$2.26M |
| 5 |
NUVL
Nuvalent
NUVL
|
+$2.23M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 43.71% |
| 2 | Technology | 17% |
| 3 | Consumer Discretionary | 6.54% |
| 4 | Energy | 4.11% |
| 5 | Consumer Staples | 3.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
151
Orthofix Medical
OFIX
$418M
| – | – |
-167,900
| Closed | -$2.44M |
|
152
Palo Alto Networks
PANW
$314B
| – | – |
-7,400
| Closed | -$1.05M |
|
153
Pliant Therapeutics
PLRX
$64.4M
| – | – |
-34,039
| Closed | -$507K |
|
|
RPTX
154
DELISTED
Repare Therapeutics
RPTX
| – | – |
-165,173
| Closed | -$778K |
|
|
SLNO
155
DELISTED
Soleno Therapeutics
SLNO
| – | – |
-10,428
| Closed | -$446K |
|
156
Syndax Pharmaceuticals
SNDX
$1.82B
| – | – |
-21,519
| Closed | -$512K |
|
157
TransDigm Group
TDG
$67.6B
| – | – |
-1,100
| Closed | -$1.35M |
|
158
Tidewater
TDW
$4.46B
| – | – |
-15,300
| Closed | -$1.41M |
|
159
Thermo Fisher Scientific
TMO
$222B
| – | – |
-1,900
| Closed | -$1.1M |
|
160
Take-Two Interactive
TTWO
$47.4B
| – | – |
-7,600
| Closed | -$1.13M |
|
161
Viatris
VTRS
$18.7B
| – | – |
-102,600
| Closed | -$1.23M |
|
162
Verizon
VZ
$195B
| – | – |
-39,100
| Closed | -$1.64M |
|
|
ALPN
163
DELISTED
Alpine Immune Sciences Inc
ALPN
| – | – |
-22,783
| Closed | -$903K |
|
|
SP
164
DELISTED
SP Plus Corporation
SP
| – | – |
-78,900
| Closed | -$4.12M |
|
Similar funds
SIAG
WI
MS
WTFG
VIA
A6
PI
ACM
HighVista Strategies's Q2 2024 Portfolio in Review
As of Q2 2024, HighVista Strategies held 164 positions worth $274M, down 2.4% from $280M the previous quarter. Its ten largest holdings account for 29% of the portfolio.
HighVista Strategies's Q2 2024 filing shows 33 new, 27 increased, 41 reduced and 27 closed positions. Its largest new stake was CATALENT, INC.: 75,600 shares worth $4.25M. The largest sale was SP Plus Corporation, an estimated $4.12M.
By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 45% a quarter earlier, followed by Technology and Consumer Discretionary.
- HighVista Strategies's largest Q2 2024 buy was CATALENT, INC.: 75,600 shares worth $4.25M.
- HighVista Strategies added most to Salesforce in Q2 2024, an estimated $2.28M increase.
- HighVista Strategies's biggest Q2 2024 reduction was IDEAYA Biosciences, cutting an estimated $2.31M.
- HighVista Strategies fully exited SP Plus Corporation in Q2 2024, selling an estimated $4.12M.
- HighVista Strategies's ten largest holdings make up 29% of its $274M portfolio in Q2 2024.
- HighVista Strategies opened 33 new positions and closed 27 in Q2 2024.
- HighVista Strategies's portfolio value fell 2.4% quarter-over-quarter to $274M.
Based on HighVista Strategies's 13F filing for Q2 2024, filed 14 Aug 2024.